Lecanemab (Leqembi) is an antibody treatment that clears amyloid protein to modestly slow early Alzheimer's decline, with risks of brain swelling and bleeding. It suits only people with mild cognitive impairment or mild dementia due to Alzheimer's who have confirmed amyloid buildup.
Families often ask whether the change feels noticeable day to day. The evidence shows a slower course, not improvement. This guide explains benefit size, eligibility, safety checks, and treatment steps.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How much does it help?
- Who may qualify?
- What are the main risks and safety checks?
- How is treatment given and accessed?
How much does it help?
In the 1,795-person Clarity AD trial reported in the New England Journal of Medicine, lecanemab slowed clinical decline by 27% over 18 months Clarity AD trial results. Scores worsened by 1.21 points versus 1.66 on placebo, a difference of 0.45 points. That gap means decline continued, but at a slower pace. The drug strongly lowers brain amyloid.
Imaging showed about 59 centiloids greater reduction than placebo at 18 months. Lower amyloid on a scan does not equal restored memory. Eisai and the FDA state the key limit plainly: lecanemab does not cure Alzheimer's, reverse memory loss, or help moderate-to-advanced dementia. Weigh a modest slowing against infusion burden and bleeding risk.
Who may qualify?
The Alzheimer's Association states treatment is for early disease only — mild cognitive impairment or mild dementia due to Alzheimer's with confirmed elevated beta-amyloid Alzheimer's Association treatment guide. A clinical diagnosis alone is not enough.
A memory center usually confirms the stage and amyloid result. People with later dementia fall outside the studied group. Bring prior cognitive tests, imaging, and medication lists to evaluation.
- mild cognitive impairment attributed to Alzheimer's
- mild dementia attributed to Alzheimer's
- confirmed elevated beta-amyloid by PET scan or spinal-fluid testing
What are the main risks and safety checks?
FDA prescribing information carries a boxed warning for amyloid-related imaging abnormalities, including swelling and tiny bleeds or surface iron deposits, plus infusion reactions and headache FDA prescribing information. People with two copies of the ApoE ε4 gene face markedly higher risk. ApoE testing and baseline plus serial MRIs are required.
Monitoring is frequent, not optional. Expect a baseline MRI, then scans generally before the 5th, 7th, and 14th infusions, with extra early checks now advised. Report new headache, confusion, dizziness, vision change, or weakness promptly. Clinicians may pause or stop infusions based on imaging or symptoms.
How is treatment given and accessed?
The FDA label directs 10 mg/kg intravenously over about one hour every two weeks. Treatment continues long term unless safety findings or disease progression change the plan. Each visit means travel, infusion time, and observation time.
Medicare covers lecanemab under Part B only through a Coverage with Evidence Development program. Both patient and clinician must enroll in a CMS-approved registry. In practice, care happens at specialized centers with infusion and MRI capacity. Ask the center how visits, MRIs, and registry enrollment are scheduled before seeking referral.





